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Enteroviruses (EVs) are recognized as the major etiological agent in meningitis in children and young
adults. The use of molecular techniques, such as PCR, has substantially improved the sensitivity of enterovirus
detection compared to that of virus culture methods. PCR-based methods also can detect a much wider range
of EV variants, including those within species A, as well as human parechoviruses (HPeVs) that often grow
poorly in vitro and which previously have been underdiagnosed by traditional methods. To exploit these
developments, we developed a real-time one-step reverse transcription-PCR (RT-PCR) for the rapid and
sensitive detection of EV and HPeV in clinical specimens. Two commercially available RT-PCR kits were used
(method I, Platinum one-step kit; method II, Express qPCR one-step kit) with primers and probes targeting
the EV and HPeV 5-untranslated regions (5UTR). Amplification dynamics (threshold cycle [CT]values and
efficiencies) of absolutely quantified full-length RNA transcripts representative of EV species A to D and HPeV
were similar, demonstrating the effectiveness of both assays across the range of currently described human EV
and HPeV variants. Probit analysis of multiple endpoint replicates demonstrated comparable sensitivities of
the assays for EV and HPeV (method I, approximately 10 copies per reaction for both targets; method II, 20
copies per reaction). CT values were highly reproducible on repeat testing of positive controls within assays and
between assay runs. Considering the sample turnaround time of less than 3 h, the multiplexed one-step
RT-PCR method provides rapid diagnostic testing for EV and HPeV in cases of suspected central nervous
system infections in a clinically relevant time frame.
Human enteroviruses (EV) and parechoviruses (HPeV),
within the virus family Picornaviridae, mostly infect children
and young adults. Enteroviruses traditionally were divided into
polioviruses (PVs; 3 serotypes), coxsackie A viruses (CAVs; 23
serotypes), coxsackie B viruses (CBVs; 6 serotypes), and echo-
viruses (E; 28 serotypes), mainly on the basis of their patho-
genicity in laboratory animals. More recently discovered
enteroviruses have been assigned enterovirus type numbers
based on the chronological order in which they were identified
(34 by the end of 2009). Altogether these 97 human EV types
fall into four genetically distinct species, HEV-A to HEV-D,
within the Enterovirus genus (16, 23).
The first two HPeV types were isolated more than 50 years
ago (25) and were described as echoviruses 22 and 23. Al-
though originally thought to be related to viruses in the
Enterovirus genus, sequence analysis has revealed several differ-
ences in genome structure and substantially divergent coding
sequences that justified their reclassification into a new, sepa-
rate Parechovirus genus (15). Recently, a further 12 HPeV
types known to infect humans have been identified (reviewed
in reference 13). Parechovirus infections are enteric and often
associated with mild gastrointestinal and respiratory symp-
toms, although severe neonatal diseases, including sepsis-like
illness, meningitis, encephalitis, and hepatitis, have been de-
scribed. In addition to HPeV type 3, HEV-B variants (includ-
ing CBVs, CAV9, and echoviruses) are the most commonly
identified viral cause of central nervous system (CNS)-associ-
ated infection in Europe (10, 11, 18, 26).
The diagnosis of EV and HPeV infections used to rely on
often slow, laborious, and insensitive cell culturing, which now
has been replaced largely by nucleic acid amplification tests,
such as reverse transcription-PCR (RT-PCR) targeting the
conserved 5-untranslated region (5UTR) (1, 6, 14, 21, 27).
HPeVs in particular historically have been problematic to de-
tect by virus culture and cannot be detected by routine entero-
virus RT-PCR; thus, HPeV infections long have been under-
diagnosed (2). More recently, separate real-time RT-PCR
assays for the detection of EV and HPeV have been developed
(3, 7, 17, 19, 20); the rapid molecular testing provided by these
assays for hospitalized children is important, since it has been
shown to reduce antibiotic usage, unnecessary investigations,
and duration of hospital stay (3, 17, 26). In the current study,
we have multiplexed EV and HPeV into a single, one-step
real-time RT-PCR using two assay formats generally used in
two diagnostic virology laboratories for the direct testing of
clinical specimens. These assays are based on Platinum one-
step kit or Express qPCR one-step kit methods. Both showed
high sensitivity and would allow the rapid detection of all
* Corresponding author. Mailing address: Specialist Virology Cen-
tre, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edin-
burgh EH16 4SA, United Kingdom. Phone: 44 131 242 6075. Fax: 44
131 2426008. E-mail: heli.simmonds@hotmail.com.
† These authors contributed equally to the manuscript.
 Published ahead of print on 18 May 2011.
2620
known EV and HPeV types simultaneously on a variety of
clinical specimens.
MATERIALS AND METHODS
In vitro-transcribed RNA for species A to D enteroviruses and parechovirus.
Plasmids containing the full-length sequence of five different enteroviruses,
coxsackievirus A16 (CAV16; species A), echoviruses 7 and 30 (E7 and E30;
species B), coxsackievirus A21 (CAV21; species C), enterovirus 70 (EV70; spe-
cies D), and human parechovirus type 1 (HPeV1) were kindly provided by G.
Stanway (CAV16) (22) and D. Evans (E7, E30, CAV21, and EV70). Before
transcription each plasmid was purified, linearized at the 3 end using the ap-
propriate restriction enzyme, and cleaned by phenol-chloroform extraction fol-
lowed by ethanol precipitation. These linearized plasmids consequently were
used as templates for in vitro RNA transcription using T7 RNA polymerase
(MEGAscript T7 kit; Ambion, Life Technologies, United Kingdom). After the
transcription reaction, the RNA was DNase treated (RQ1 kit; Promega, United
Kingdom) and purified using LiCl precipitation. The concentration of the RNAs
was determined using a NanoDrop ND-1000 (Thermo Scientific, United King-
dom) photospectrometer. The integrity of RNA transcripts was demonstrated by
denaturing agarose gel electrophoresis (data not shown). Tenfold dilution series
for assay calibration were made in citrate buffer (pH 6.0; Ambion, Life Tech-
nologies, United Kingdom) supplemented with 0.05 g/ml carrier tRNA and 0.1
U/ml RNAsin inhibitor. Amplification efficiencies were calculated from the gra-
dient of the line of best fit for data points of log10-transformed RNA input copies
and CT values using the following formula: 100  (101/gradient  1). Further
dilutions of E7 and HPeV1 RNA were assessed in 24 parallel reactions to
determine a 90% detection limit for the assays. Probit analysis was performed
using the SAS statistical package.
One-step RT-PCR assays. For EV amplification, primers and probe (5-TCC-
GGC-CCC-TGA-ATG-CGG-CTA-AT-3) were as described by Dierssen et al.
(7). Primers and probe [5-AAA-CAC-TAG-TTG-TA(A/T)-GGC-CC-3] for
HPeV corresponded to those described by Benschop et al. (3). In method I, the
5 and 3 ends of the EV probes were labeled with cy5 and black hole quencher
(BHQ), respectively, whereas 6-carboxyfluorescein (FAM) and minor groove
binder were used for the HPeV probe. In method II, 5 and 3 labels were FAM
and BHQ for the EV probe and Yakima yellow and BHQ for the HPeV
probe. All primers and probes were purchased from Applied Biosystems
(United Kingdom).
Beside the primers, probes, and oligonucleotides, all other reaction compo-
nents, including Superscript III, were provided with the Platinum one-step kit
(method I; Glasgow) and Express qPCR one-step kit (method II; Edinburgh).
For method I, EV primers (1 M each) and probe (0.025 M) as well as HPeV
primers (1 M each) and probe (0.05 M) were added to the master mix (15 l)
as modified from the manufacturer’s recommendations (Platinum one-step kit;
Invitrogen) (9). Purified RNA (6 l) was added to the master mix. After reverse
transcription at 50°C (15 min) and initial denaturation at 95°C (2 min), ampli-
fication was performed in 40 cycles with a standard TaqMan two-step protocol
(60°C for 34 s and 95°C for s). For method II, EV primers (0.5 M each) and
probe (0.35 M) as well as HPeV primers (0.5 M each) and probe (0.35 M)
were added to the master mix (25 l) per the manufacturer’s recommendations
(Express qPCR one-step kit; Invitrogen). Purified RNA (9 l) was added to the
master mix. After reverse transcription at 50°C (15 min) and initial denaturation
at 95°C (20 s), amplification was performed in 45 cycles with a standard three-
step protocol (55°C for 25 s, 72°C for 10 s, and 95°C for 3 s). Real-time PCR
experiments by both methods were run on an ABI Prism 7500 SDS real-time
platform (Applied Biosystems, United Kingdom).
Viral strains and quality control panels. E30 isolate cultured in RD cells as
well as HPeV1 and HPeV3 isolates cultured on Vero cells were used as assay
controls and for the efficiency testing of one-step RT-PCR. The most common
enterovirus strains, including 14 HEV-B serotypes (CBV1 to CBV5, CAV9, E3,
E6, E7, E11, E13, E18, E21, and E30; obtained from the Health Protection
Agency, Colindale, London, United Kingdom), 2 HEV-A serotypes (CAV16 and
EV71; obtained from the Health Protection Agency, Colindale, London, United
Kingdom), and 24 previously typed clinical parechovirus isolates (13 HPeV1, 4
HPeV3, 2 HPeV4, 4 HPeV5, and 1 HPeV6; kindly provided by Katja Wolthers,
Amsterdam Medical Centre, Netherlands) were analyzed. The sensitivity and
specificity of one-step EV and HPeV RT-PCR was evaluated using all 12 samples
(EVRNA10-1 to EVRNA10-12) from the 2010 proficiency panel obtained from
Quality Control on Molecular Diagnostic (QCMD) by both assays.
Clinical samples. Total RNA from clinical samples was extracted from 200 l
cerebrospinal fluid (CSF) with the Qiagen MDx using the QIAamp viral RNA kit
(method II; Qiagen, United Kingdom) or using the bioMe´rieux easyMag
(method I; bioMe´rieux, France) and was eluted in 50 l corresponding dilution
buffer. Purified RNA (9 l) was subjected to a study of EV and HPeV RNA
detection by the one-step RT-PCR, the established diagnostic real-time RT-PCR
for EV (modified from reference 7), and in-house nested RT-PCR assay for
HPeV (12). Their diagnostic specificity was confirmed with 120 CSF samples
(method II).
RESULTS
Sensitivity of one-step RT-PCR. To compare the sensitivities
of method I and II one-step RT-PCRs for the four species of
human enteroviruses, duplicate dilution series of RNA tran-
scripts derived from the full-length clones of CAV16 (EV-A),
E30 E7 (EV-B), CAV21 (EV-C), and EV70 (EV-D) were
assayed, and CT values were recorded (Fig. 1). All five entero-
FIG. 1. Amplification of RNA transcripts of defined concentrations by method I (Platinum RT-PCR) (A) and method II (Express qPCR)
(B) multiplex assays. CT values (y axis) were plotted for serial 10-fold dilutions of each transcript (x axis).
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virus transcripts showed efficient amplification by both meth-
ods; a linear line of the best fit of CT values (y axis) with
log-transformed RNA input copies (x axis) showed amplifica-
tion efficiencies ranging from 92 to 111% (mean, 105%; slopes,
3.08 to 3.54; correlation coefficient [R2], 0.9812 to 0.9998)
in method I and 95 to 105.5% (mean, 100%; slopes, 3.21 to
3.44; R2, 0.9949 to 1.000) in method II. Although CT values
from method II were approximately 3 cycles greater for a given
transcript concentration compared to that of method I, both
assays showed highly reproducible detection abilities for tran-
scripts from the four EV species, the only exception being the
species C transcript in method I (CT values were 4 cycles
higher than those observed with species A, B and D; Fig. 1A,
green line). Parechovirus amplification was comparable be-
tween the two methods (assay efficiencies were 108 and 97%
and R2 was 0.9995 and 0.9977 for methods I and II, respec-
tively) (Fig. 1).
By testing a much larger number of replicates around the
endpoint of the EV and HPeV assays, the 90% detection
frequencies were calculated by probit analysis (Table 1). The
90% detection limit of 7 copies per reaction (95% confidence
interval [CI], 4 to 16 copies) for E7 and 9 copies per reaction
(95% CI, 5 to 30 copies) for HPeV1 were predicted for method
I. For method II, the corresponding 90% detection thresholds
were 19 copies (CI, 11 to 50 copies) for E7 and 21 copies (CI,
17 to 32 copies) for HPeV1.
A panel consisting of 16 EV serotypes (CBV1 to CBV5,
CAV9, CAV16, E3, E6, E7, E11, E13, E18, E21, E30, and
EV71) and 5 HPeV types (HPeV1, HPeV3, HPeV4, HPeV5,
and HPeV6) was tested. All (sero)types were efficiently ampli-
fied and sensitively detected, as evidenced by low CT values
(data not shown). The one-step RT-PCR method was used to
screen the QCMD panels for the detection of enteroviruses
and parechoviruses. In the duplicate testing of the 2010
QCMD panel sample, EVRNA10-12 (107 dilution of E11)
was detected only once by method II, whereas all other EV
(107 dilution of E30, CAV9, and EV71; 106 dilution of
CBV3; 105 dilution of E11, E30, CAV9, and EV71)- and
HPeV (106 and 104 dilutions of HPeV3)-positive samples,
and a negative sample, were scored correctly in both assays.
Comparison with singleplex RT-PCR for EV and HPeV.
Multiplexed RT-PCR for EV and HPeV was compared to the
single RT-PCR assays to investigate whether multiplexing the
PCR influenced assay sensitivity. Using the published one-step
RT-PCR for EV detection (7), all five RNA transcripts tested
in duplicate were positive for 80 copies (10/10 combined), 7/10
were positive for 8 copies, and 0/10 were positive for 0.8 copies
of RNA used per reaction. These are comparable to detection
frequencies in both multiplexed assays (Table 1). Further sen-
sitivity comparisons between assays (multiplexed RT-PCR for
EV and HPeV detection and singleplex RT-PCR for EV and
HPeV detection) were made by assaying RNA extracted from
a 10-fold dilution series of culture supernatant from an in vitro
isolate of EV species B, E30, and two HPeVs (types 1 and 3)
by methods I and II. Both assays and methods showed equal
endpoint dilutions (105 for E30 and 107 for HPeV1 and
HPeV3), providing further evidence that multiplexing did not
affect the sensitivity of RT-PCR.
Specificity and reproducibility of one-step RT-PCR for EV
and HPeV detection. Cross-reactivity with viruses commonly
present in clinical specimens was analyzed by both methods.
The common respiratory pathogens (including influenza vi-
ruses [A, A/H1N1, and B], parainfluenza viruses [types 1 to 4],
respiratory syncytial virus, human metapneumovirus, corona-
viruses [229E, OC43, NL63, and HKU1], adenovirus, Pneumo-
cystis jirovecii, and Mycoplasma pneumoniae), viruses causing
gastroenteritis (norovirus and rotavirus) and rash (measles vi-
rus), various herpesviruses (herpes simplex virus types 1 and 2,
varicella-zoster virus, Epstein-Barr virus, and cytomegalovi-
rus), and mumps virus all tested negative by methods I and II.
Similarly, the interassay reproducibility was evaluated by mon-
itoring CT values from the positive controls (E30 and HPeV3)
across 20 RT-PCR runs and intra-assay reproducibility by test-
ing the controls in 20 wells on a single RT-PCR run by both
methods (Table 2).
Evaluation of one-step RT-PCR for diagnostic EV and HPeV
detection in CSF samples. A total of 120 anonymous CSF
samples obtained from patients with suspected meningitis or
neonatal sepsis-like disease were evaluated. After RNA extrac-
TABLE 1. Detection limit of one-step RT-PCR as determined
by serial endpoint dilutions of in vitro-transcribed E7 and
HPeV1 RNAa
Method and no. of RNA
copies/reaction
No. (%) of positive results for virus:
E7 HPeV1
I
600 24/24 (100) 8/8 (100)
60 4/4 (100) 8/8 (100)
6 21/24 (88) 20/24 (83)
0.6 2/24 (8) 5/24 (21)
II
900 4/4 (100) 4/4 (100)
90 20/20 (100) 4/4 (100)
20 22/24 (92) 21/24 (88)
6 15/24 (63) 1/24 (4)
0.9 5/24 (21) 0/24 (0)
a The 90% detection limit with a 95% confidence interval (CI) was calculated
by probit analysis. Method I and II 90% detection limits (95% CI) for E7 were
7 (4 to 16) and 19 (11 to 50) RNA copies/reaction, respectively, and for HPeV1
they were 9 (5 to 30) and 21 (17 to 31) RNA copies/reaction, respectively.









Mean SD Max Min
Intertest
I EV 26.23 0.57 27.94 24.51 0.0217
HPeV 27.02 0.48 28.45 25.6 0.0178
II EV 31.96 0.36 32.66 31.27 0.0113
HPeV 26.86 0.32 27.31 26.23 0.0119
Intratest
I EV 24.84 0.34 25.86 23.83 0.0137
HPeV 27.34 0.28 28.81 26.51 0.0102
II EV 29.01 0.48 29.74 28.13 0.0165
HPeV 27.54 0.35 28.03 27.02 0.0127
a Maximum (max) and minimum (min) values are within 3 SD from the
mean CT.
b CV, coefficient of variation.
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tion from CSF, results from EV and HPeV RNA detection by
the one-step multiplexed RT-PCR (method II) were compared
to the established diagnostic real-time RT-PCR for EV (mod-
ified from reference 7) and in-house nested RT-PCR assay for
HPeV (12). Both RT-PCR methods gave concordant results (8
EV positive, 7 HPeV positive, and 105 negative), indicating the
100% sensitivity and specificity of one-step RT-PCR compared
to those of single real-time RT-PCR for EVs and nested RT-
PCR for HPeVs. Molecular typing by VP1 sequencing for EVs
and VP3/VP1 for HPeVs were achieved in all samples: CAV9
(5), CAV6 (1), E6 (1), E30 (1), and HPeV3 (7).
DISCUSSION
The newly developed one-step real-time RT-PCR proto-
col(s) enables the rapid and simultaneous diagnosis of entero-
virus and human parechovirus RNA in clinical specimens. The
one-step RT-PCR protocol combined reverse transcription
and DNA amplification in a single closed tube and allowed
convenient real-time detection of specific amplicons for assay
specificity. The sensitivity and specificity of the assay imple-
mented in the widely used Platinum one-step and Express
qPCR one-step kits were equivalent despite considerable dif-
ferences in thermal cycling, annealing temperatures, and reac-
tion buffer components. These results indicate that the multi-
plexed format as well as primer and probe combinations are
relatively robust and can be incorporated into a wider range of
assay formats.
Previous evaluations of the EV primers and probe in a
nonmultiplexed one-step RT-PCR format demonstrated a sen-
sitivity of 100 copies of EV RNA per reaction, corresponding
to approximately 3,800 copies/ml of CSF (7). Nonmultiplexed
detection for HPeV by one-step real-time RT-PCR showed a
100% detection limit of 30 RNA copies per reaction, derived
from testing 30 replicates (19). Although an optimized two-
step real-time RT-PCR assay for EVs was shown to be more
sensitive than the one-step method, reaching a detection limit
of about 10 to 50 genomes per reaction (17), the recent studies
using SuperScript III confirmed that the one-step RT-PCR
method can have sensitivity equal to (if not better than) that of
two-step reactions (19, 24). This was indeed seen in our study,
with 90% detection limits of approximately 10 copies for both
analytes in method I and 20 copies in method II. This corre-
sponds to approximately 420 copies/ml of CSF for method I
with currently used test volumes (RNA extracted from 200 l
CSF into an elution volume of 50 l; 6 l was used in the PCR;
the effective test volume was 24 l) and 550 copies/ml in
method II (200 l CSF, with an elution volume of 50 l; 9 l
was used in the PCR; the effective test volume was 36 l). A 5-
to 10-fold increase in diagnostic sensitivity could be achieved
with large sample volume extractions and increasing the
amount of RNA added to the PCR (150- to 300-l effective
volumes; 30 to 70 RNA copies/ml in CSF using method I, 70 to
130 copies/ml using method II).
The equivalent amplification efficiency and sensitivity of the
assay for target sequences of all four EV species provides
reassurance that a wide range of EV variants can be detected
by the multiplexed assay. In particular, it directly addresses the
concern arising from the previous use of cell culture-based
diagnostic methods that species A variants often were under-
diagnosed because of their poor in vitro replication (2, 4).
Similarly, the absence of species C or D nonpoliovirus EV
types in diagnostic specimens, screened to provide direct evi-
dence for their lack of CNS-associated presentations (or sep-
sis-like illness) in the target population, does not reflect a lack
of assay sensitivity (10). This is despite the wide circulation of
species C enteroviruses in the community (4), as also deter-
mined by recent environmental surveillance (E. C. M. Leitch,
J. S. Calvert, H. Harvala, and P. Simmonds, unpublished data).
Furthermore, for species C this is particularly important in
view of the previous transportation of wild poliovirus serotype
1 into Europe, the first report since the European regions were
declared polio-free in 2002 ( 5, 8), and validates the assay for
current enhanced enterovirus surveillance.
For more than for any other sample type, high sensitivity and
specificity is needed for CSF screening. Viral loads frequently
are extremely low, close to or below assay sensitivity levels due
to the limited penetration of virus into the CNS and because
sampling often is conducted in the resolution phase of the
acute infection, when symptoms may be most pronounced but
systemic viral loads are rapidly falling. In further contrast to
other specimen types, because of its ability to cross the blood-
brain barrier, the detection of EV or HPeV in CSF specimens
usually should be regarded as significant and potentially caus-
ative of the disease presentations. The introduction of the
highly sensitive, rapid screening of patients presenting with
meningitis or other neurological symptoms thus has the ability
to considerably improve their clinical management. Although
EV and HPeV infections cannot be directly treated, rapid test
results (within hours of obtaining a sample) will, for example,
reduce hospital attendance and shorten the duration of anti-
biotic treatment (17, 26). The screening assay described in the
current study provides the means to rapidly detect the two
viruses most closely linked with CNS-associated infections, in-
cluding viral meningitis, and its format represents a useful
template for multiplexing further diagnostic targets.
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